On March 12, 2014, Depomed, Inc. (NASDAQ:DEPO) reported financial results for the fourth quarter and full year ended December 31, 2013. Total revenues in the quarter were $40.6 million, comprised of $18.8 million in product sales, $18.5 million in royalties (of which $18.1 million was non-cash associate with the PDL BioPharma transaction), and $3.3 million in licensing and collaborative fees. Revenues blew away our expectations of $20.1 million, but we note we did not expect the $18.1 million non-cash revenues during the quarter. Backing-out this accounting, the company's top-line results for the quarter of $22.5 million still handsomely beat our estimate.
Getting to the $18.1 million, we remind investors that back in October 2013, Depomed sold certain interests...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|